February 27, 2017- Hideki Ueyama, MD ; Yoshio Matsui, MD , PhD; Yukihide Minoda, MD , PhD; Masanori Matsuu ra, MD ; Hiroaki Nakamura, MD , PhD Total knee arthroplasty (TKA) is one of the most successful surgeries for patients with degenerative joint dis­ease, and many studies have shown good results from TKA.1-3 Implant alignment … Continued

Entrepreneurs Philip Hyun & Fraser Townley are hoping to entice the MVP panel with their new gaming control, Game Vice. Will these entrepreneurs recruit new brand ambassadors for their company or will they get stuck sitting on the bench?  Watch to find out what happens.

Washington, DC – September 20, 2016—ClearFlow Inc., a medical device company based in Anaheim, CA, participated in a series of panel presentations related to the clinical and economic benefits of maintaining chest tube patency following cardiothoracic surgery last Friday at a session sponsored during the Cardiovascular-Thoracic (CVT) Critical Care Conference in Washington DC. Clinical cardiac … Continued

Elsloo, THE NETHERLANDS – September 28, 2016 — ClearFlow, Inc., a medical device company headquartered in Anaheim, California and with a European office in Amsterdam, has announced the opening of its new dedicated European Service Center near Maastricht, the Netherlands. ClearFlow is the maker of the PleuraFlow® Active Clearance Technology® System, which proactively prevents or … Continued

Anaheim, CA – November 15, 2016. ClearFlow, Inc., a medical device company based in Anaheim, California has announced the publication of positive results in a clinical trial evaluating the PleuraFlow® Active Clearance Technology® System. Data indicating a marked reduction in Retained Blood Syndrome (RBS) among patients recovering from implantation of left ventricular assist devices (LVAD) … Continued

Anaheim, CA – January 31, 2017—Clinical study results presented at the Society of Critical Care Medicine (SCCM) 46th Annual Critical Care Congress in Honolulu last week suggest that all heart surgery patients are at risk for Retained Blood Syndrome, not just high-risk patients, as previously assumed. All patients having heart surgery are required to have … Continued

Ablexis Continues Expansion of List of Licensees of AlivaMab Mouse BURLINGAME, Calif., Jan. 12, 2017 (GLOBE NEWSWIRE) — Ablexis, LLC announced today that it has entered into a non-exclusive, perpetual license agreement with the Tri-Institutional Therapeutics Discovery Institute (Tri-I TDI) in New York City to provide access to the AlivaMab Mouse for antibody drug discovery … Continued